Carbonic anhydrases II, IX, and XII in Barrett’s esophagus and adenocarcinoma by Nortunen, Minna et al.
1 
Carbonic Anhydrases II, IX, and XII in Barrett’s Esophagus and Adenocarcinoma 
Minna Nortunen1, Heikki Huhta1, Olli Helminen1, Seppo Parkkila3,4, Joonas H Kauppila1,2, Tuomo 
J Karttunen,1* and Juha Saarnio1* 
*indicated authors contributed equally as last author
Affiliations: 
1Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of 
Oulu and Oulu University Hospital, 90014 Oulu, Finland, 2Upper Gastrointestinal Surgery, 
Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University 
Hospital, 17176 Stockholm, Sweden, 3Faculty of Medicine and Life Sciences, University of 
Tampere, Finland, and 4Fimlab Ltd, Tampere University Hospital, 33520 Tampere, Finland 
Corresponding author: Minna Nortunen  minna.nortunen@gmail.com  
+358 8 3152875 
16-digit ORCID id: 0000-0003-0928-150X 
Word count: 2922 
Keywords: CAII, CAIX, CAXII, Esophageal adenocarcinoma, Barrett’s esophagus 
Acknowledgments: The present study was funded by Sigrid Juselius Foundation (JHK), Orion 
Research Foundation (JHK), The Finnish Cancer Foundation (JHK, HH), Mary and Georg C. 
Ehrnroots Foundation (JHK, HH), Thelma Mäkikyrö Foundation (JHK, HH), Päivikki and Sakari 
Sohlberg’s foundation (HH) and Finnish medical foundation (HH). 
This is the post print of the article, which has been published in Virchows archiv. 2018, 437 (5),567-575.  
http://doi.org/10.1007/s00428-018-2424-z.  
 2 
Abstract 
 
The aim of our retrospective study was to investigate the expression and clinical significance of the 
cancer-associated carbonic anhydrases (CAs) II, IX, and XII in Barrett’s esophagus and esophageal 
adenocarcinoma (EAC). We evaluated 101 archival specimens from patients with EAC as well as 
seven and 26 samples from patients with high-and low-grade dysplasia, respectively. In addition, 
normal esophageal squamous epithelium, gastric and intestinal metaplasia were analyzed when 
present. The expression patterns of isozymes were detected by immunohistochemistry. CAII and 
CIX expression levels were lower in the squamous epithelium than in the columnar cells while 
CAXII showed an opposite pattern and was present mainly in squamous epithelium. Expression 
patterns in benign, dysplastic, or malignant esophageal columnar lesions were not significantly 
different. The assessment of clinicopathological associations showed that CAII was significantly 
downregulated in metastatic disease (p=0.026). CAIX showed no association with prognosis, 
although there appeared to be an association (p=0.056) between high expression and nodal spread. 
In conclusion, CAII, CAIX, and CAXII do not serve as biomarkers for different phases in the 
development of EAC. 
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Introduction 
The incidence of esophageal adenocarcinoma (EAC) is rapidly increasing in Western countries. In 
the U.S., the incidence rose nearly 5-fold from 1975 to 2009 [1]. The prognosis is still 
unsatisfactory despite initial curative surgery, with an overall 5-year survival of only 22% [2]. 
Barrett’s esophagus, a complication of gastroesophageal reflux disease, is a well-recognized 
precursor to EAC via columnar epithelium dysplasia [3, 4]. Carbonic anhydrases (CAs) are zinc-
containing metalloenzymes catalyzing the reversible hydration of CO2 to bicarbonate and hydrogen 
ions. So far 12 catalytically active isoforms have been found in humans [5]. Cytosolic CAII and the 
membrane bound isoforms, CAIX and CAXII, are often considered tumor-associated CAs [6]. The 
basic function of these enzymes is to regulate the pH homeostasis of the body [7], but they also 
have other important physiological roles, such as regulation of glycolysis, gluconeogenesis, and 
CO2 transport [8]. The majority of primary and metastatic cancers primarily show glycolytic 
metabolism even in the presence of oxygen [9]. Another key feature in cancer pathophysiology is 
tumor acidity [10-12]; CAII, CAIX, and CAXII may play important roles in acidifying the tumor 
microenvironment and maintaining upregulated tumor glycolysis. Recently, a dual role was 
proposed for CAII in intracellular pH regulation and exportation of excess lactate by supporting 
monocarboxylate transporters, namely MCT1 and MCT4 [13]. Extracellular acidosis on the other 
hand is largely due to extracellular facing CAIX and CAXII leading to CO2 hydration and 
subsequent hypercapnic acidosis [10]. In addition, CAIX and CAXII play an important role in the 
regulation of intracellular pH [14] together with cytosolic CAII.  Thus, crucial features of tumor 
progression, such as energy transport and pH regulation, are partly CA-dependent processes [14, 
15]. 
 
Carbonic anhydrase II is the most widely distributed isoform in the human body and is present 
throughout the gastrointestinal tract [7]. Significant downregulation of CAII expression is 
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associated with poor survival in various cancers, such as pancreatic and gastric adenocarcinomas 
[16, 17]. The CAIX and CAXII isoforms are hypoxia-inducible and strongly regulated by HIF-
1alpha [14]. The expression of CAIX is very limited in normal, non-malignant human tissues [7]. In 
most solid tumors investigated [14, 18-20], high CAIX expression is associated with a poor 
prognosis, and CAIX inhibitors are being avidly researched as a cancer treatment. Although a 
similar association has been reported in EAC by Birner et al. [21], other studies have had restricted 
sample sizes [22, 23] or the results have been controversial [24]. CAXII is expressed in many 
tissues, such as breast, renal, large intestine, and to some extent gastric mucosa [25]. It is also found 
in several cancers [25-27] with a variable association with the overall survival. In squamocellular 
esophageal carcinoma, CAXII has been described as a marker of poor prognosis [26].  
 
No previous studies have examined the role of CAII or CAXII in EAC or its precursor lesions. The 
role of CAIX is controversial in the light of previous reports. The aim of this study was to describe 
the expression patterns of CAII, CAIX, and CAXII in Barret’s esophagus with or without dysplasia 
and in EAC. We also analyzed whether the expression of any of these isozymes is associated with 
the prognosis of EAC patients.  
 
 
Materials and methods 
 
Patients 
 
The paraffin-embedded archival specimens from patients with EAC and associated Barrett’s 
esophagus between the years 1987-2013 were obtained from the Department of Pathology, Oulu 
University Hospital, Oulu, Finland. A major part of the same series has been previously reported in 
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studies describing Toll-like receptors (TLRs) [28,29]. For the current report, we updated the follow-
up data. The series consisted of 101 patients with EAC, seven patients with high-grade dysplasia, 
and 26 patients with low-grade dysplasia as the most advanced lesion. The median age of the 
patients was 63 years (range 43-91). There were 71 (70%) patients who died during follow-up. The 
median follow-up time of the surviving patients was 20 months (range 0-288 months). The patients’ 
survival data were acquired from the Statistics Finland and the other relevant data from the patients’ 
records at Oulu University Hospital.  The patients’ data are summarized in Table 1. The use of the 
patients’ samples and the data inquiry were approved by the Oulu University Hospital Ethics 
Committee and by the National Authority for Medicolegal Affairs (VALVIRA). 
 
Immunohistochemistry 
Immunohistochemistry was performed on sections of tissue blocks that were first selected by an 
expert gastrointestinal pathologist to be representative using hematoxylin-eosin stained sections. 
The CA immunostaining was conducted at the Department of Anatomy, University of Tampere 
using polyclonal rabbit anti-human CAII and CAXII sera and monoclonal anti-human CAIX 
antibody (M75), as described previously for polymer-based detection [5]. The antibodies have been 
previously characterized and are specific for each isozyme [30-32]. 
 
Assessment of CA expression 
The histological sample slides were digitized using an Aperio AT2 Console (Leica Biosystems 
Imaging Inc., Nussloch, Germany). Different lesions in the specimens were identified and marked 
by an expert gastrointestinal pathologist (T.J.K.). CA immunoreactivity was analyzed by three 
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independent researchers who were blinded from the clinical data [28]. In assessment of staining 
intensity, internal positive controls were used; parietal cells for CAII and CAIX, red blood cells for 
CAII and suprabasal cells of the normal squamous epithelium for CAXII. The staining intensity (0-
3) and the proportion (percentage) of stained cells (0-100%) were separately assessed in the 
epithelial cells of all evaluated lesions. Mean values of the three independent estimates were used if 
the estimates did not differ by more than 1 in the intensity assessment or more than 30% in the 
percentage assessment. If the estimates differed over these limits, a consensus was reached after re-
evaluation. The mean intensity and mean percentage were then multiplied together and the CA 
histoscore (0-300) was obtained. Histoscore values were further dichotomized into two equally 
sized groups by the median value for each CA isozyme.   
 
Statistical analysis 
For statistical analyses, we used IBM SPSS Statistics 23.0 (IBM Corp., Armonk, NY, USA). To 
compare CA expression levels between different lesions, we used one way ANOVA and we used 
the Tukey honest significant difference test in post hoc analysis. The chi-squared test was used to 
calculate the statistically significant differences between prognostic and clinicopathological 
variables. Life tables were calculated according to the Kaplan–Meier method and the survival 
curves were compared using the log rank test.  
 
Results 
 
Expression patterns of CAII, CAIX, and CAXII in esophageal squamous epithelium, Barrett’s 
esophagus, dysplasia, and adenocarcinoma 
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Expression levels of CAII, CAIX, and CAXII in different esophageal lesions are summarized in 
Table 2, and examples of the characteristic staining patterns are shown in Figure 1. Epithelial 
expression of CAII was present in all the esophageal lesions assessed (Table 2; Figure 1). The 
expression was mostly cytoplasmic, as expected, but was also found in nuclei occasionally. In the 
normal squamous epithelium, CAII typically showed diffuse expression throughout (Figure 1; D, 
E). In gastric metaplasia of the esophagus, the staining intensity was significantly stronger 
compared with normal epithelium and adenocarcinoma. The strongest staining was present in the 
parietal cells and superficial parts of the gland (Figure 1; A-B). When comparing gastric and 
intestinal metaplasia, CAII expression appeared weaker in the latter and the staining intensity grew 
stronger towards the surface of the mucosa (Figure 1; B, C, E). In low- and high-grade dysplastic 
regions, the staining was generally spread very diffusely, but no significant differences emerged 
compared with non-dysplastic columnar epithelium or carcinoma.  In adenocarcinomas, the 
intensity of the staining was weaker than in gastric metaplasia. It typically represented diffuse 
cytoplasmic staining with a weak-to-moderate intensity (Figure 1; A, D).  
 
Expression of CAIX was membrane bound, as reported previously [31]. There was practically no 
staining of CAIX in the normal squamous epithelium (Figure 1; I, J). Expression in gastric 
metaplasia was strong and present in all cell types across the epithelium (Figure 1; F, G). There was 
a decrease in the expression from gastric metaplasia to intestinal metaplasia to dysplastic lesions to 
adenocarcinoma (Figure 1; F-J).). In intestinal metaplasia, the expression was still strong and 
showed the highest basal staining (Figure 1; H, J). A similar pattern was seen in the dysplastic 
lesions, which showed the staining intensifying towards the basal region of the gland. However, the 
overall expression was weaker than in the non-dysplastic columnar epithelium. The differences in 
histoscores between gastric metaplasia and high- and low-grade dysplastic lesions were significant 
 8 
(Figure 1; H ;Table 2). The CAIX expression in the adenocarcinoma samples was variable. It was 
mostly weak or absent (Figure 1; F, I), but a few cancers stained very intensely. Yet, the mean 
histoscore for adenocarcinomas was significantly lower than for metaplasias and low-grade 
dysplasia (Table 2).  
 
The CAXII expression was mostly limited to the normal squamous epithelium, where the staining 
was present in the cell membranes and concentrated in the basal parts of the epithelium (Figure 1; 
N-O). Metaplastic lesions, low-grade dysplasia, and adenocarcinomas showed weak or absent 
expression for CAXII (Figure 1; K-M, O). In high-grade dysplastic lesions, expression of CAXII 
tended to more abundant, but no significant differences emerged (Figure 1; N).  
 
Correlation of CA expression with clinicopathological variables and survival in EAC 
 
A low CAII histoscore was associated with the presence of distant metastases (Table 3; p=0.026). A 
similar association was also observed with the staining intensity and percentage of positive cells. 
The expression of CAIX tended to be higher with lymph node positive disease (Table 3; p=0.056). 
Expression of CAII, CAIX, or CAXII showed no other significant associations with 
clinicopathological features, including age, gender, tumor node metastasis (TNM) classification, or 
the stage or grade of differentiation of the tumor (Table 3). To emphasize the early stages of 
carcinogenesis, we also analyzed CA expression levels in pT1a (n=7) and pT1b (n=8) tumors and 
found again no significant differences. The CAII, CAIX, or CAXII expression patterns did not 
associate with survival in Kaplan-Meier analyses and therefore multivariable tests were not 
performed. 
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 Discussion  
This study describes the expression patterns of the cancer-associated CAII, CAIX, and CAXII, in 
normal esophageal squamous epithelium, precancerous lesions, and EAC. There was expression of 
CAII and CAIX in all the epithelial types, except for the normal squamous epithelium where 
expression of CAIX was weak or absent. The CAXII staining was strong in the normal squamous 
epithelium, but absent or only very weakly present in the columnar lesions. In carcinomas, low 
CAII levels were associated with distant metastases (p=0.026). The CAIX expression was 
consistently decreased in more malignant lesions. In carcinomas there seemed to be an association 
between high CAIX expression and nodal spread (p=0.056). CAII, CAIX and CAXII did not 
associate with prognosis.  
In the esophageal squamous epithelium, CAII was constantly present, as described previously [7, 
33, 34]. It showed a diffuse, cytoplasmic staining pattern with the strongest signal in the suprabasal 
layer.  This expression pattern is consistent with the role of CAII in epithelial defense against acid 
reflux [34]. No previous data have been reported on CAII in esophageal, gastric, or intestinal 
metaplasia or dysplasia and adenocarcinoma. We found extensive expression of CAII in esophageal 
gastric metaplasia and especially in metaplastic parietal cells, mostly in a pattern similar to that 
reported in the gastric mucosa [33]. Expression of CAII was slightly weaker in esophageal intestinal 
metaplasia and the staining tended to accentuate in the superficial parts of the metaplastic area. This 
could point to CAII playing a role in cell maturation in intestinal metaplasia, since CAII is similarly 
concentrated in the apical parts of the intestinal villi [33]. In the dysplastic columnar metaplasia, the 
expression intensity of CAII was comparable to non-dysplastic columnar metaplasia. Interestingly, 
the staining was more widely distributed across both the bases and superficial parts of dysplastic 
columnar metaplasia (Figure 1C), correlating with either the extension of the cell proliferation zone 
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or lesser surface maturation in dysplasia [35, 36]. However, due to the overlap in its staining 
distribution, CAII does not appear to be a biomarker of Barrett’s dysplasia.  
 
In adenocarcinomas, the level of CAII expression was significantly lower than in columnar 
metaplasia, but did not differ from dysplasia. Downregulation of CAII was significantly associated 
with metastatic disease, although there was no association with survival.  In gastric cancer, low 
CAII expression correlates with tumor size, distant metastasis, TNM-stage, and poorer overall 
survival [16, 37]. In addition, expression of CAII has been reported significantly downregulated in 
metastatic gastric cancer cells [38]. In vitro studies have suggested that the enzyme has inhibitory 
effects on the growth of colorectal cancer cells [39] and similary as in gastric cancer, CAII has been 
identified as a metastasis-associated factor in colorectal carcinoma by analysis of gene expression 
profiles [40]. The mechanisms linking low or absent CAII expression with metastasis are unknown. 
To point out, a lack of CAII protects tumor cells from the extracellular pH fluctuations common in 
carcinomas, possibly stabilizing carcinoma cell functions [41]. In Xenopus oocytes, CAII has a non-
catalytic function as a facilitator of transmembrane ion shuttles [13], such as the monocarboxylate 
transporters MCT1 and MCT4. These transporters of high energy metabolites, such as lactate, are 
upregulated in EAC [42] and various other carcinomas. Altogether, these data suggest the 
mechanisms linking downregulation of CAII and metastatic behaviour should be investigated 
further.  
 
Expression of CAIX in the normal esophageal squamous epithelium was nearly absent in our 
samples, similar to what Turner et al. reported previously [23]. In esophageal gastric metaplasia, the 
CAIX staining was strong and covered the full depth of the epithelium, corresponding with CAIX 
expression in the gastric mucosa [31]. The expression showed a non-significant decrease in 
esophageal intestinal metaplasia, where there was also a decreasing gradient towards the surface. A 
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similar pattern of CAIX expression has been reported in gastric intestinal metaplasia [43] and large 
intestinal mucosa [44], corresponding with the location of proliferating cells. The functional 
significance of the observed decrease in expression on the surface is unknown. However, a recent 
animal study found that CAIX plays an important role in the gastric barrier function against luminal 
acid [45], suggesting that downregulation in esophageal intestinal metaplasia could be involved in 
acid reflux-related damage. The decreasing trend in CAIX expression continued in low- and high-
grade dysplasia, again in the same manner as has been described for low- and high-grade dysplastic 
adenomas in the stomach [43]. In dysplasia, as in intestinal metaplasia, the staining was confined to 
the basal and suprabasal parts. The expression of CAIX in preneoplastic lesions and Barrett’s 
esophagus has been reported in two previous studies concerning EAC [21, 24]. Both these reports 
state, congruent to our results, that precancerous lesions and especially non-dysplastic metaplasias 
had higher expression levels of CAIX than adenocarcinomas. 
 
The CAIX expression in carcinomas showed no significant correlation with clinicopathological 
variables or survival; although, high CAIX expression appeared to associate (p=0.056) with nodal 
spread. The expression of CAIX in EAC has been studied before with controversial results [21-24]. 
Turner et al. originally reported CAIX (MN antigen) expression in EAC in 1997 with only 10 
patients and suggested loss of CAIX expression was associated with cancer progression [23].  In 
2008, Driessen et al. [22] published a population of 39 EAC patients and found a survival benefit 
for CAIX-negative cancers. However, gastric and cardiac cancer patients were included in their 
survival analysis. Birner et al. [21] showed in a larger study (n=182) that overexpression of CAIX 
in EAC is strongly associated with shorter overall and disease-free survival. In 2015, Huber et al. 
[24] reported on a series of 123 EAC patients and found no association between the expression of 
CAIX and prognosis. For gastric cancer, the published results are also ambiguous, reporting a 
survival benefit for CAIX-negative [22] cancers or no association with survival [46, 47] at all.  
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It might be worth considering whether there is any biological plausibility in the controversial 
observations of the prognostic value of CAIX in EAC and gastric cancer. Chen et al. [48] found that 
CAIX expression is frequently lost in gastric cancers; however, the expression can be restored and 
the tumors re-expressing CAIX have a poorer prognosis. This sequence supports the findings from 
studies where CAIX overexpression indicated poor prognosis [21, 22]. Thus, could be suggested, 
that the expression of CAIX is dynamic, fluctuating during carcinogenesis and tumor progression, 
and may explain its varying prognostic value [21-24]. There is a question raised whether 
immunohistochemistry at any given time is the best way to assess CAIX expression in tumors. For 
instance, the methylation status of CAIX  [48] in gastric cancer was associated with lymph node 
metastasis; whereas, expression analyzed by immunohistochemistry was not associated with 
clinicopathological parameters. The same study also demonstrated that although HIF1-alfa is 
induced, the expression of CAIX in gastric cancer is probably also regulated by site-specific 
methylation and not merely by hypoxia. This could explain, for instance, Birner’s [21] finding that 
HIF1-alpha and CAIX levels had no clear correlation and explain why CAIX is not expressed or 
associated with survival categorically in all hypoxic tumors.  
 
We consistently found strong CAXII expression only in the parabasal cells of normal esophageal 
squamous epithelium with a membrane-bound pattern, as has been described before[26]. In other 
esophageal lesions studied, including adenocarcinomas, the expression was practically absent with 
no association with survival or clinicopathological parameters. There are no previous studies about 
CAXII in esophageal columnar metaplasia or adenocarcinoma. Our findings suggest that CAXII 
does not play any important role in the pathogenesis of dysplastic metaplasia or EAC. In other 
cancer types, the correlation of CAXII with prognosis has varied, with some reports linking CAXII 
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overexpression with poor survival [26, 27] and some with a good prognosis [49] or better 
radiotherapy outcomes [50].  
 
In conclusion, the cancer-associated CAII, CAIX, and CAXII all have characteristic expression 
patterns in EAC, its precursor lesions, and normal squamous epithelium. In EAC, CAII 
downregulation is associated with metastatic disease. CAIX expression is lost towards the more 
malignant lesions, but in lymph node positive disease, the expression seems to be again higher. 
Finally, CAXII is only expressed in the normal esophageal squamous epithelium and there is no 
evidence for its role in EAC or precursor lesions. 
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Figure Captions: 
Fig.1 Examples of typical expression patterns of CAII (left panel; A-E), CAIX (middle panel, F-J), 
and CAXII (right panel, K-O) in different esophageal lesions. Each row shows a corresponding 
field of a case. A, F, and K represent a sample showing gastric metaplasia with cardiac-type mucosa 
(right) and adenocarcinoma (left). B, G and L show esophageal gastric body type metaplasia. C, H 
and M demonstrate a high-grade dysplasia lesion (right) bordering with non-dysplastic intestinal 
metaplasia (left). D, I, and N show the border of esophageal squamous epithelium and 
adenocarcinoma. E, J, and O show squamous epithelium (left) and intestinal metaplasia (right). 
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Table 1. Baseline characteristics of the study population 
with esophageal adenocarcinoma (EAC), high-grade 
dysplasia (HGD), and low-grade dysplasia (LGD) 
 
EAC HGD LGD 
n=101 n=7 n=26 
Age at diagnosis    
<60 years 37/101 2/7 7/26 
60-65 years 19/101 2/7 3/26 
>65 years 45/101 2/7 16/26 
Sex    
Male 82/101 7/7 17/26 
Female 19/101 0/7 9/26 
Tumor   
T1 17/100   
T2 16/100   
T3 51/100   
T4 16/100   
Lymph nodes   
negative 41/100   
positive 59/100   
Organ metastases   
negative 69/100   
positive 31/100   
Grade   
1 35/98   
2 26/98   
3 37/98   
Stage   
I 14/100   
II 39/100   
III 15/100   
IV 32/100   
Tumor size   
small (<40mm) 40/93   
large (≥40mm) 53/93     
TNM-staging was available for 100, grade of 
differentiation for 98, and tumor size for 93 patients  
Table 2. Baseline characteristics of CAII, CAIX, and CAXII expression in normal 
esophageal squamous epithelium and in different esophageal lesions  intensity intensity statistical histoscore histoscore statistical 
CAII mean 95% CI significance mean 95% CI significance 
Normal 
epithelium 1.3 1.1-1.4  74 56-94  
Gastric 
metaplasia 1.9 1.7-2.0 a 116 95-138  
Intestinal 
metaplasia 1.4 1.2-1.7  72 48-98  
Low-grade 
dysplasia 1.7 1.5-1.9  95 72-121  
High-grade 
dysplasia 1.9 1.5-2.2  139 97-179  
Adenocarcinoma 1.4 1.2-1.6 b 81 62-101  
       
CAIX       
Normal 
epithelium 0.6 0.3-0.8   13 5-25   
Gastric 
metaplasia 2.4 2.2-2.5 a 211 191-232 a 
Intestinal 
metaplasia 2.2 2.0-2.5 a 163 134-192 a 
Low-grade 
dysplasia 1.9 1.6-2.1 a 144 116-172 ab 
High-grade 
dysplasia 1.7 1.3-2.0 a 100 62-143 ab 
Adenocarcinoma 1.8 1.5-2.0 ab 78 63-92 abcd 
       
CAXII       
Normal 
epithelium 2.2 2.0-2.4   142 122-159   
Gastric 
metaplasia 0.5 0.3-0.7 a 13 7-21 a 
Intestinal 
metaplasia 0.4 0.3-0.6 a 11 5-18 a 
Low-grade 
dysplasia 0.4 0.2-0.5 a 12 5-21 a 
High-grade 
dysplasia 0.8 0.5-1.0 a 37 21-56 a 
Adenocarcinoma 0.4 0.3-0.5 a 15 8-23 a 
       
The histoscore was calculated by multiplying the staining intensity (0-3) with the percentage of positive cells 
(0-100%), resulting in a value between 0 and 300. Values are presented as the mean and 95% confidential 
interval (95%CI). For statistical testing, we used one way ANOVA with Tukey test in post hoc analysis. a 
Compared with normal epithelium, p<0.05; b compared with gastric metaplasia, p<0.05; c compared with 
intestinal metaplasia, p<0.05; d compared with low-grade dysplasia, p<0.05 
Table 3. The relationship between CAII, CAIX, and CAXII histoscores and the clinicopathological variables in esophageal 
adenocarcinoma 
Variable n/N(%) CA II histoscore n(%)   CA IX histoscore n(%)   CA XII histoscore n(%) 
    weak strong p   weak strong p   weak strong p 
pT             
 T 1-2 33/100(33%) 9 24 0.465  16 17 0.537  21 12 0.39 
 T 3-4 67/100(67%) 27 40   27 40   50 17  
Lymph nodes             
negative 41/100(41%) 15 26 0.542  22 19 0.056  31 10 0.268 
positive 59/100(59%) 21 38   21 38   40 19  
Organ metastases             
negative 69/100(69%) 20 49 0.026  27 42 0.172  49 20 0.587 
positive 31/100(31%) 16 15   16 15   22 9  
Grade             
1 35/98(36%) 8 27 0.268  15 20 0.99  25 10 0.365 
2 27/98(28%) 11* 15*   12 15   16 11  
3 37/98(38%) 16 21   16 21   29 8  
Stage             
I 14/100(14%) 4 10 0.184  6 8 0.387  10 4 0.775 
II 39/100(39%) 13 26   16 23   29 10  
III 15/100(15%) 3 12   4 11   9 6  
IV 32/100(32%) 16 16   17 15   23 9  
Tumor size             
     small (<40mm) 40/93(43%) 12 28 0.178  19 21 0.357  27 13 0.269 
     large (>40mm) 53/93(57%) 22 31     22 31     40 13   
*CAII staining only available for 26 grade 2 tumors due to paraffin blocks running out 
